Press Room


    Press Release - February 13, 2001

    Benoit La Salle Joins Pheromone Sciences Board of Directors Benoit La Salle Joins Pheromone Sciences Board of Directors

    Toronto, Ontario (February 13, 2001) - Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Mr. Benoit La Salle to its Board of Directors

    Mr. La Salle, a Chartered Accountant, is a member of the Quebec Order of Chartered Accountants, the Canadian Institute of Chartered Accountants, the Order of Chartered Administrators of Quebec and the Quebec Institute of Financial Planners. In 1980, Mr. La Salle founded the firm of Grou, La Salle & Associes, Chartered Accountants. Mr. La Salle holds extensive experience in matters relating to public companies.

    Active in the public markets, Mr. La Salle is currently the President and Chief Executive Officer of Semafo Inc., a TSE listing firm engaged in mining activities in West Africa. In addition, he serves on the board of directors of a number of public companies including Bio-Capital and Bridgepoint International Inc. and as both a member of the board of directors and audit committee of The Canam Manac Group, Vasogen Inc., Pebercan Inc., and Electromed Imaging Inc.

    "We are delighted to have Benoit La Salle accept a position on the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Mr. La Salle adds extensive business experience and financial expertise that will benefit the Company as we continue to advance the commercial development of our products."

    Mr. La Salle holds a commerce degree from McGill University and a master of business administration from IMEDE in Switzerland. He is involved in a number of charitable organizations including that of the Ecole Buissoniere Foundation and Foster Parents Plan Canada.

    The appointment, which is subject to regulatory approval, is part of an on-going program to enhance the independent nature of the Board. As such, the Board has accepted the resignation of Douglas Marett. Mr. Marett remains a member of senior management retaining the position Vice- President and Chief Scientific Officer.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News